Abstract
Background The recent COVID-19 epidemic in mainland China is an important issue for studying the prevention and disease control measures and the spread of the COVID-19 epidemic. Following our previous study for the mainland China epidemic during December 6 2021 to 30 April 2021, this paper studies and compares the the mainland China epidemic during December 6 2021 to December 6, 2022.
Methods Using differential equations and real word data (both domestic and foreign input infected individuals) modelings and simulates COVID-19 epidemic in mainland China during May 1 2021 to December 6 2022, estimates the transmission rates, the recovery rates, and the blocking rates to the symptomatic and the asymptomatic infections.
Results The simulation results were in good agreement with the real word data.
The average input transmission rate of the foreign input symptomatic infection individuals was much lower than the average transmission rate of the symptomatic infection causing by the mainland symptomatic individuals;
The average input transmission rate of the foreign input asymptomatic infection individuals was was much lower than the average transmission rate of the asymptomatic infection causing by the mainland symptomatic individuals;
The average recovery rates of the foreign input COVID-19 symptomatic and asymptomatic infected individuals were much higher than the average recovery rates of the mainland COVID-19 symptomatic and asymptomatic infected individuals, respectively.
For the mainland epidemic simulations
If kept the transmission rates, the recovery rates, the death rate and the blocking rates on day 181 (June 30, 2022), the numbers of the current symptomatic and asymptomatic individuals would reduce to about one on day 277 (October 4, 2022).
If kept the transmission rates, the recovery rates, the death rate and the blocking rates on day 340 (December 6, 2022) until day 377 (January 16, 2023), the numbers of the current symptomatic and the asymptomatic infected individuals would increase to 38896 and 230924, respectively, the cumulative death individuals would increase from 599 to 615, respectively.
If kept the transmission rates, the recovery rates on day 340, but decreased the blocking rates to 30% and select the death rate to equal to the average death rate during days 104-150, then the simulation showed that on day 377, the numbers of current symptomatic and the asymptomatic infected individuals would increase to about 33 723 8057 and 501 626 885, respectively, and the cumulative death individuals would reach about 1 012 543.
For the foreign input epidemic simulations:
If kept the transmission rates, the recovery rates, and the blocking rates day 242 (August 30, 2022), until day 340, the numbers of the current symptomatic and the asymptomatic infected individuals would decrease to 13 and 430, respectively.
If kept the transmission rates, the recovery rates, the death rate and the blocking rates on day 340 until day 377 (January 16, 2023), the numbers of the current symptomatic and the asymptomatic infected individuals would decrease and increase to 185 and 1935, respectively.
Recommendations on COVID-19 epidemic base on WHO’s technic guidelines and HBV Infection in Chimpanzees are provided.
Conclusions
For the mainland individuals’ epidemic, keeping the blocking rates of over 86% and 93% to the symptomatic and asymptomatic infections, and the recovery rates of over 0.119 and 0.112 to the symptomatic and asymptomatic individuals may make the numbers of the current symptomatic and asymptomatic infected individuals to decrease to very low levels in three months.
For the foreign input individuals’ epidemic, keeping the transmission rates of under 0.07 to the symptomatic and asymptomatic infections, and the recovery rates of over 0.125 and 0.099 to the symptomatic and asymptomatic individuals may make the numbers of the current symptomatic and asymptomatic infected individuals to decrease to very low levels in four months.
After December 6, 2022, decreasing the blocking rates of under 30% to the symptomatic and asymptomatic infections may cause over 800 millions individuals’ COVID-19 infections and over 10 millions COVID-19 infected individuals’ death.
It is necessary that administrations implement strict prevent and control strategies to prevent the spread of new COVID-19 variants.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
